GLP-1 receptor agonists
US$ 25.35
tirzepatide in uk first country Europe to reimburse Tried everything but still struggling
Description
Thankfully, there are new weapons in the
Well on GLP-1s: Simple and Satisfying).
A Google Sheets version is provided for teams that prefer Sheets, though some Excel formatting may display slightly differently after import
Our white paper, "Breaking the GLP-1 Cost Cycle," explores the complexities of the obesity crisis and reveals two innovative solutions designed to improve health outcomes and generate savings for employers
By early 2025, nearly 25% of diabetes patients had started a GLP1 therapy, up from just 3% four years ago
This estimate is based on the medication's...
